Heron Therapeutics, Inc. (HRTX) stock
Close on Nov 17, 2026Market cap $53.58MP/E –Yield –
Earnings
Heron Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Heron Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 9, 2026before the open | $35.30M | -7.6% | -$0.03 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 10, 2026before the open | $37.70M | +1.3% | -$0.03 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 11, 2026before the open | $34.70M | -10.8% | -$0.04 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $40.59M | – | -$0.02 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $38.20M | +16.4% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 8, 2025before the open | $37.20M | +3.3% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025before the open | $38.90M | +12.1% | $0.01 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | $32.81M | +4.4% | -$0.03 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024during market hours | $36.00M | +13.3% | -$0.06 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024before the open | $34.70M | +17.2% | -$0.02 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 12, 2024during market hours | $34.23M | +14.1% | -$0.07 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 14, 2023during market hours | $31.43M | +18.2% | -$0.17 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023during market hours | $31.76M | +15.1% | -$0.35 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | $29.60M | +26.0% | -$0.27 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 23, 2023during market hours | $30.00M | +44.9% | -$0.17 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022during market hours | $26.60M | +14.7% | -$0.38 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022before the open | $27.60M | – | -$0.55 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022during market hours | $23.50M | – | -$0.63 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022during market hours | $20.70M | – | -$0.54 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021during market hours | $23.20M | – | -$0.51 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 24, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Heron Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Net RevenueGAAP | FY2026 | $173.00M – $183.00M | – | New | May 11, 2026 |
| Net Revenue | FY2026 | $173.00M – $183.00M | – | New | Feb 26, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $10.00M – $20.00M | $10.00M – $20.00M | Reaffirmed | May 11, 2026 |
Guidance vs results
The last range Heron Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $153.00M – $163.00M | $154.89MΣ4Q | Within range |
| Q4 FY2022 | Revenue growth | +30% – +40% | +44.93% | Above range |
| Q3 FY2022 | Revenue growth | +40% – +50% | +14.66% | Below range |
| Q2 FY2022 | Revenue | $22.00M – $23.00M | $27.60M | Above range |
| Q1 FY2022 | Revenue | $20.00M – $22.00M | $23.50M | Above range |
| Q4 FY2021 | Revenue | $20.00M – $22.00M | $20.70M | Within range |
Guidance history
Every forecast Heron Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| May 11, 2026 | Adjusted EBITDA | FY2026 | $10.00M – $20.00M | Reaffirmed |
| May 11, 2026 | Net Revenue | FY2026 | $173.00M – $183.00M | New |
| Feb 26, 2026 | Adjusted EBITDA | FY2026 | $10.00M – $20.00M | New |
| Feb 26, 2026 | Net Revenue | FY2026 | $173.00M – $183.00M | New |
| Nov 4, 2025 | Adjusted EBITDA | FY2025 | $9.00M – $13.00M | New |
| Nov 4, 2025 | Net Revenue | FY2025 | $153.00M – $163.00M | New |
| Aug 8, 2025 | Adjusted EBITDA | FY2025 | $9.00M – $13.00M | Raised |
| Aug 8, 2025 | Net Revenue | FY2025 | $153.00M – $163.00M | Reaffirmed |
| May 6, 2025 | Adjusted EBITDA | FY2025 | $4.00M – $12.00M | New |
| May 6, 2025 | Net Revenue | FY2025 | $153.00M – $163.00M | New |
| Nov 12, 2024 | Adjusted EBITDA | FY2024 | $2.00M – $5.00M | Raised |
| Nov 12, 2024 | Adjusted Operating Expenses | FY2024 | $101.00M – $105.00M | Lowered |
| Nov 12, 2024 | Net Revenue | Q4 FY2024 | $37.00M – $43.00M | New |
| Nov 12, 2024 | Product Revenues, Net | FY2024 | $140.00M – $146.00M | Narrowed |
| Aug 6, 2024 | Adjusted EBITDA | FY2024 | -$10.00M – $3.00M | Raised |
| Aug 6, 2024 | Adjusted Operating Expenses | FY2024 | $107.00M – $111.00M | Lowered |
| Aug 6, 2024 | Product Revenues, Net | FY2024 | $138.00M – $158.00M | Reaffirmed |
| May 7, 2024 | Adjusted EBITDA | FY2024 | -$22.00M – $3.00M | Reaffirmed |
| May 7, 2024 | Adjusted Operating Expenses | FY2024 | $108.00M – $116.00M | Reaffirmed |
| May 7, 2024 | Product Revenues, Net | FY2024 | $138.00M – $158.00M | Reaffirmed |
| Mar 12, 2024 | Adjusted EBITDA | FY2024 | -$22.00M – $3.00M | Reaffirmed |
| Mar 12, 2024 | Adjusted Operating Expenses | FY2024 | $108.00M – $116.00M | Reaffirmed |
| Mar 12, 2024 | Product Revenues, Net | FY2024 | $138.00M – $158.00M | New |
| Nov 14, 2023 | EBITDA (excluding stock compensation) | Q4 FY2023 | -$10.00M – -$6.00M | New |
| Nov 14, 2023 | EBITDA (excluding stock compensation) | FY2024 | -$22.00M – $3.00M | New |
| Nov 14, 2023 | Gross margin | FY2024 | 69% | New |
| Nov 14, 2023 | Gross margin | FY2023 | 41% | New |
| Nov 14, 2023 | operating expenses (excluding stock compensation, depreciation and amortization) | FY2024 | $108.00M – $116.00M | New |
| Nov 14, 2023 | net product sales | FY2023 | $123.00M – $125.00M | Raised |
| Nov 14, 2023 | net product sales | FY2024 | $138.00M – $158.00M | New |
| Aug 14, 2023 | oncology care franchise net product sales | FY2023 | $99.00M – $103.00M | Reaffirmed |
| Mar 23, 2023 | ZYNRELEF demand unit sales | Q1 FY2023 | +10% | New |
| Mar 23, 2023 | net product sales for the oncology care franchise | FY2023 | $99.00M – $103.00M | New |
| Nov 8, 2022 | net product sales for the oncology care franchise | FY2022 | $93.00M – $95.00M | Reaffirmed |
| Nov 8, 2022 | ZYNRELEF net product sales | Q4 FY2022 | +30% – +40% | New |
| Aug 9, 2022 | net product sales for the oncology care franchise | FY2022 | $93.00M – $95.00M | Raised |
| Aug 9, 2022 | ZYNRELEF net product sales | Q3 FY2022 | +40% – +50% | New |
| May 9, 2022 | net cash used for operating activities | Q2 FY2022 | $37.00M – $39.00M | New |
| May 9, 2022 | net product sales for the oncology care franchise | Q2 FY2022 | $22.00M – $23.00M | New |
| May 9, 2022 | net product sales for the oncology care franchise | FY2022 | $89.00M – $93.00M | New |
| Feb 28, 2022 | net cash used for operating activities | Q1 FY2022 | $44.00M – $48.00M | New |
| Feb 28, 2022 | net product sales for the oncology care franchise | Q1 FY2022 | $20.00M – $22.00M | New |
| Nov 3, 2021 | net cash used for operating activities | Q4 FY2021 | $45.00M – $48.00M | New |
| Nov 3, 2021 | net product sales for the oncology care franchise | Q4 FY2021 | $20.00M – $22.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Heron Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- Results
- Results
- Update
- Results
- Update
- News
- Results
- Results
- Results
- News
- Results
See a number that looks wrong?